Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.

Vivos Therapeutics, Inc., a company listed in the US under the stock code VVOS, has been informed by the United States Securities and Exchange Commission (SEC) that its recently filed Registration Statement on Form S-1 will not undergo review. The statement, filed on April 9, 2024, with the file number 333-278564, was acknowledged by the SEC in a letter addressed to R. Kirk Huntsman, the Chief Executive Officer of Vivos Therapeutics. The SEC's correspondence, dated April 12, 2024, also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. The SEC's Division of Corporation Finance, Office of Industrial Applications and Services, directed any further questions to Jane Park and provided her contact information.